logo.png
GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia
June 27, 2024 09:15 ET | GT Biopharma, Inc.
GTB-3650 Phase 1 trial initiation expected in H2 2024; initial clinical data expected in H1 2025GTB-5550 TriKE® IND submission for treatment of B7H3 positive solid tumors expected in Q1 2025GTB-5550...
OPEN SANS HH STACKED_2.jpg
New Research Confirms Hb Variant Test for Sickle Cell, Gazelle™, Useful for Screening and Tracking Treatment Management in Remote Settings, Advancing Doctors’ Abilities to Better Detect and Manage the Disease
June 20, 2024 08:00 ET | Hemex Health
PORTLAND, Ore. and ACCRA, Ghana, June 20, 2024 (GLOBE NEWSWIRE) -- Hemex Health announced that the results of two investigations into the effectiveness of their Gazelle™ point-of-care Hb Variant...
ElmediX_blue_horizontal
ElmediX Plans Series A Round Based on Strong Signals in a Clinical Study for Pancreatic Cancer Patients at the University Hospital Antwerp (Belgium)
June 14, 2024 08:03 ET | Elmedix
A novel and innovative approach to treating metastasized cancer, starting with the very lethal grade 4 pancreatic cancer.  Earlier this year, scientists from Columbia University in New...
Logo.png
GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor Pitch Conference
June 11, 2024 09:00 ET | GRI Bio, Inc.
Live video webcast on Tuesday, June 18th at 11:00 AM ET LA JOLLA, CA, June 11, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio,” “we,” “our,” or the “Company”), a biotechnology...
Webinar Presenter
Neurocognitively-Defined Subtypes in Bipolar Disorder: A Path to More Personalized Treatments - A Free Webinar from the Brain & Behavior Research Foundation
June 03, 2024 13:19 ET | Brain & Behavior Research Foundation
New York, June 03, 2024 (GLOBE NEWSWIRE) -- NEW YORK -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “Neurocognitively-Defined Subtypes in Bipolar Disorder: A Path...
ACF logo RGB - Used for Digital and MS Office (1).png
Alberta Cancer Foundation announces new Breakthrough Fund recipient, driving commercial success of cancer research breakthroughs
May 31, 2024 12:00 ET | Alberta Cancer Foundation
Alberta Cancer Foundation announces new Breakthrough Fund recipient, driving commercial success of cancer research breakthroughs Local startup Oncobiotix
dew-logo.png
Dew Aesthetics Unveils Cutting-Edge MedSpa Treatments in Baltimore, Pioneering a Path to Timeless Beauty
May 15, 2024 10:00 ET | Dew Aesthetics
BALTIMORE, Md., May 15, 2024 (GLOBE NEWSWIRE) -- Dew Aesthetics, the premier destination for cutting-edge medical spa treatments, is proud to announce the launch of its innovative services,...
Logo.png
GRI Bio to Present at Alliance Global Partner’s 2024 Healthcare Company Showcase
May 14, 2024 09:05 ET | GRI Bio, Inc.
Live webcast fireside chat on Tuesday, May 21st at 2:40 PM ET LA JOLLA, CA, May 14, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company...
Picture1.jpg
ONCOTELIC PRESENTING AT BIOPHARMA NEXUS CONFERENCE SAN DIEGO 2024
May 08, 2024 08:00 ET | Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its presentation at Biopharma Nexus Conference. Dr. Andy Hu, Nanomedicine Manager,...
Palisade Bio_Logos(4.22)VSM.png
Palisade Bio Announces Closing of $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules
May 07, 2024 07:30 ET | Palisade Bio, Inc.
Carlsbad, CA, May 07, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with...